Opeongo
Opeongo is a frontier AI company building foundation models of the extracellular matrix (ECM), the body-wide network that records injury and governs tissue behavior. Its Meshwork Virtual Machine, trained on proprietary assays developed over two decades, decodes ECM remodeling, predicts tissue responses, and simulates therapeutic interventions before they reach patients, targeting systemic diseases like fibrosis, chronic inflammation, and aging.
- Drug Discovery & Therapeutics
- Artificial Intelligence
- Biotechnology
- Healthcare Technology
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Current approaches to modeling human biology reconstruct the body piece by piece—genome, cell, organ, tumor—but these silos never cohere into a faithful model of the whole organism. Systemic diseases such as fibrosis, chronic inflammation, and aging are distributed across tissues, making them difficult to understand or treat when studied only at the cellular or molecular level.
Solution
Opeongo builds the Meshwork Virtual Machine, the first foundation model of the extracellular matrix (ECM) and its remodeling dynamics. The ECM is a dynamic, body-wide network that surrounds every cell, records every injury, and instructs cellular behavior. Opeongo's model runs on proprietary assay data collected over two decades that capture the matrix in motion across human tissue. The model decodes how the matrix changes, predicts how tissue will behave, and simulates therapeutic interventions before they reach a patient, making the broader landscape of human health legible and actionable.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing therapies for fibrosis, chronic inflammation, aging, and other systemic diseases, as well as researchers seeking to understand tissue-level pathology and therapeutic response.
Features
- Foundation model of the ECM and its remodeling dynamics, trained on proprietary assay data collected over two decades
- Proprietary assays that capture the matrix in motion across human tissue, generating data not previously available
- Capability to decode ECM changes, predict tissue behavior, and simulate interventions before patient exposure
- Focus on systemic phenomena including fibrosis, chronic inflammation, and aging that are distributed across tissues
- Built on the insight that the ECM is governed by a constrained set of master regulators, making it tractable to computation